Abstract:Vesicular stomatitis virus (VSV) is a promising vector for vaccine and oncolysis, but it can also produce acute diseases in cattle, horses, and swine characterized by vesiculation and ulceration of the tongue, oral tissues, feet, and teats. In experimental animals (primates, rats, and mice), VSV has been shown to lead to neurotoxicities, such as hind limb paralysis. The virus matrix protein (M) and glycoprotein (G) are both major pathogenic determinants of wild-type VSV and have been the major targets for the production of attenuated strains. Existing strategies for attenuation included: (1) deletion or M51R substitution in the M protein (VSVΔM51 or VSVM51R, respectively); (2) truncation of the C-terminus of the G protein (GΔ28). Despite these mutations, recombinant VSV with mutated M protein is only moderately attenuated in animals, whereas there are no detailed reports to determine the pathogenicity of recombinant VSV with truncated G protein at high dose. Thus, a novel recombinant VSV (VSVΔM51-GΔ28) as well as other attenuated VSVs (VSVΔM51, VSV-GΔ28) were produced to determine their efficacy as vaccine vectors with low pathogenicity. In vitro studies indicated that truncated G protein (GΔ28) could play a more important role than deletion of M51 (ΔM51) for attenuation of recombinant VSV. VSVΔM51-GΔ28 was determined to be the most attenuated virus with low pathogenicity in mice, with VSV-GΔ28 also showing relatively reduced pathogenicity. Further, neutralizing antibodies stimulated by VSV-GΔ28 proved to be significantly higher than in mice treated with VSVΔM51-GΔ28. In conclusion, among different attenuated VSVs with mutated M and/or G proteins, recombinant VSV with only truncated G protein (VSV-GΔ28) demonstrated ideal balance between pathogenesis and stimulating a protective immune response. These properties make VSV-GΔ28 a promising vaccine vector and vaccine candidate for preventing vesicular stomatitis disease.

PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum

PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver

Site-Specific PEGylated Adeno-Associated Viruses with Increased Serum Stability and Reduced Immunogenicity.

Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions

Regulation of Transduction Efficiency by Pegylation of Baculovirus Vector in Vitro and in Vivo

Polyethylenimine Coating To Produce Serum-Resistant Baculoviral Vectors For In Vivo Gene Delivery

Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector

Neutralizing Antibody Evasion Ability Of Adenovirus Vector Induced By The Bioconjugation Of Methoxypolyethylene Glycol Succinimidyl Propionate (Mpeg-Spa)

Evaluation of Attenuated VSVs with Mutated M Or/and G Proteins As Vaccine Vectors

Linear and multivalent PEGylation of the tobacco mosaic virus and the effects on its biological properties

Pegylated Adenovirus Vectors Containing Rgd Peptides on the Tip of Peg Show High Transduction Efficiency and Antibody Evasion Ability

Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus

Hexon-specific PEGylated adenovirus vectors utilizing avidin-biotin interaction

An efficient plasmid-based system for the recovery of recombinant vesicular stomatitis virus encoding foreign glycoproteins

Optimization of the VSV G backbone for amino terminal fusion with nanobodies allowing its retargeting to receptors of therapeutic interest.

P11-04. PEGylated Poly [2-(N,n-dimethylamino) Ethyl Methacrylate] As Mucosal DNA Delivery Vector Improves HIV-1-specific Immune Responses

Efficient inhibition of C-26 colon carcinoma by VSVMP gene delivered by biodegradable cationic nanogel derived from polyethyleneimine.

Design and selection of anti-PD-L1 single-domain antibody and tumor necrosis factor superfamily ligands for an optimal vectorization in an oncolytic virus

Preparation of Monopegylated Cyanovirin-N's Derivative and Its Anti-Influenza A Virus Bioactivity in Vitro and in Vivo.

Linker-Extended Native Cyanovirin-N Facilitates PEGylation and Potently Inhibits HIV-1 by Targeting the Glycan Ligand